Prospective Observational Epidemiologic Study of Maraviroc's Safety

Trial ID or NCT#

NCT00665561

Status

not recruiting iconNOT RECRUITING

Purpose

The study will assess if use of maraviroc along with an optimized background regimen of antiretroviral drugs in usual clinical practice is as safe as using only an optimized regimen of antiretroviral drugs.

Official Title

AN INTERNATIONAL, MULTICENTER, PROSPECTIVE OBSERVATIONAL STUDY OF THE SAFETY OF MARAVIROC USED WITH OPTIMIZED BACKGROUND THERAPY IN TREATMENT-EXPERIENCED HIV-1 INFECTED PATIENTS

Eligibility Criteria

Ages Eligible for Study: Older than 18 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No
Inclusion Criteria:
  1. - Treatment experienced, HIV-1 infected patients - 18 years or older - Receive an approved assay for determination of HIV-1 tropism
Exclusion Criteria:
  1. - Pregnant or lactating - Using CCR5 inhibitor other than maraviroc
View All Criteria
Show Less

Investigator(s)

Philip Grant
Philip Grant
Positive care doctor, Infectious disease doctor
Clinical Associate Professor, Medicine - Infectious Diseases
Andrew Zolopa

Contact us to find out if this trial is right for you.

Contact

Debbie Slamowitz
(650) 723-2808

View on ClinicalTrials.gov